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192Spleen Tyrosine Kinase Mediates EGFR
Signaling to Regulate Keratinocyte
Terminal Differentiation
Nan-Lin Wu1,2,3, Duen-Yi Huang4, Li-Fang Wang5, Reiji Kannagi6, Yu-Ching Fan4 and Wan-Wan Lin4,7Spleen tyrosine kinase (Syk), a nonreceptor tyrosine kinase, was initially identified as a crucial regulator in
proximal immunoreceptor signaling. Additional studies have revealed its pleiotropic roles, and drugs targeting
Syk are under development for inflammatory diseases. Syk expression in the skin has been detected, but its
functions in the skin are still unknown. Here, we found that Syk phosphorylation and expression in primary
human keratinocytes decreased gradually along with terminal differentiation. Human skin specimens showed
similar in vivo patterns. Syk inhibitors or knockdown of Syk increased the expression of differentiation markers
under in vitro differentiation models. Furthermore, EGFR activation prominently induced Syk phosphorylation,
which could be inhibited by the EGFR inhibitor gefitinib or knockdown of EGFR. The Src inhibitor also partially
attenuated EGF-induced phosphorylation of Syk. However, Syk inhibition suppressed EGF-induced phos-
phorylation of EGFR. Immunoprecipitation and confocal microscopy further revealed the increased molecular
interaction between EGFR and Syk after EGF stimulation. This study unravels the role of Syk in EGFR-mediated
signaling and reveals regulatory roles of Syk in keratinocyte differentiation, suggesting the clinical potential of
topical or systemic Syk inhibitors in the treatment of skin diseases with aberrant differentiation.
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Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine kinase
first found in hematopoietic lineage cells. Syk contains two
tandem SRC homology 2 domains, a linker region, and one
carboxy-terminal tyrosine kinase domain (Mocsai et al.,
2010). Syk-deficient mice suffer severe hemorrhage and
blocked B-cell development and die perinatally (Cheng
et al., 1995; Turner et al., 1995). Syk is a crucial regulator
in the proximal signaling of various receptors involved in
innate and adaptive immunity (Jung et al., 1999; Turner
et al., 2000). In the immunoreceptor tyrosine-based acti-
vation motif (ITAM)- and hemiITAM-based signaling
downstream of B-cell receptors, T-cell receptors, and Fc
receptors, Syk recruitment to dual-phosphorylated ITAM
triggers Syk activation, leading to diverse cellular responses
(Mocsai et al., 2010). Syk plays a dual role in the toll-like
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Epidermal keratinocytes, the principal cell component in
the skin, undergo continuous terminal differentiation to
construct the outermost cornified layer of the skin, a process
named cornification (Candi et al., 2005). Cornification is
considered a model of cell death and is characterized by
the activation of caspase 14, a nonapoptotic caspase
(Galluzzi et al., 2012). Epidermal keratinocytes sequentially
express distinct differentiation marker proteins such as
transglutaminase (TGase) types 1, 3, and 5; involucrin,
keratin 1/10; loricrin; and profilaggrin, which act as either
enzymes or substrates to establish the skin barrier (Candi
et al., 2005; Eckert et al., 2005). During the terminal dif-
ferentiation process, proliferating keratinocytes gradually
become growth arrested and eventually dead cornified
keratinocytes. During this process EGFR expression and
activation are downregulated (King et al., 1990; Nanney
et al., 1984).
Based on the well-known immunologic functions of Syk
(Mocsai et al., 2010; Yanagi et al., 2001), the application of
pharmacologic inhibitors that suppress Syk function has been
investigated for the treatment of lymphoma, leukemia,
asthma, allergic rhinitis, lupus erythematosus, and rheuma-
toid arthritis (Riccaboni et al., 2010). However, compared
with the wide exploration of Syk functions in immunologic
diseases, its role in normal epithelial organs such as the skin
is less clear. In this study, using immunohistochemistry, Syk
inhibitors, and Syk knockdown in primary human epidermal
keratinocytes, we found that Syk is involved in terminal dif-
ferentiation of keratinocytes and participates in EGFR-
mediated signaling, indicating an important role of Syk in
skin biology.s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Syk activation and expression are regulated during
keratinocyte terminal differentiation
To evaluate the in vivo pattern of Syk activation and phos-
phorylation, we performed immunohistochemical staining to
analyze the expression of Syk and phosphorylated Syk in
normal and psoriatic skin tissues. As shown in Figure 1a, c, e,
and g, phosphorylated Syk expression was detected in the
epidermis and was relatively prominent in the lower
epidermis. Notably, phosphorylated Syk was obviously
expressed in the cell membranes of keratinocytes (Figure 1a,
c, e, and g, inlets). Similarly, Syk expression was low in the
uppermost part of the epidermis. Phosphorylated Syk was
expressed more highly in keratinocytes in psoriasis samples
than in normal skin (Figure 1i and j).
Next, to investigate whether the abundant expression of Syk
in primary cultured normal human epidermal keratinocytes
(NHEKs) can be changed during keratinocyte differentiation,
we used cell confluence and phorbol 12-myristate 13-acetate
(PMA) to induce keratinocyte differentiation. As shown in
Figure 1k, when NHEKs were cultured for 4 days to reach
confluence, Syk mRNA expression was strongly suppressed.
The expression levels of Syk and phosphorylated Syk
decreased gradually after 4-day culture, irrespective of growth
factors in the culture medium. When PMA was applied, Syk
mRNA expression in NHEKs was decreased, especially after
treatment for 24 hours. Reductions in Syk and phosphorylated
Syk expression byPMAwere also observed, especiallyat a high
concentration of PMA (100 nM, 24 hours) or at the late time
point (30 nM, 48 hours) (Figure 1l). Comparedwith confluence
and PMA, the suppressive effect of calcium, another
differentiation-inducing agent in cultured NHEKs, on Syk
expression was weak (see Supplementary Figure S1, online).
Inhibition of Syk promotes keratinocyte terminal
differentiation
The use of pharmacologic inhibitors of Syk has been explored
to treat diverse inflammatory diseases. Thus, we evaluated
the potential effects of pharmacologic inhibitors of Syk in
keratinocytes. We used R406, an active metabolite of fosta-
matinib, to treat NHEKs and detected increased mRNA
expression of various differentiation markers, including
involucrin, TGase 1, keratin 10, and loricrin. The induction of
keratin 10 by R406 was especially prominent (Figure 2a). As
shown in Figure 2b and c, R406 induced the protein
expression of various differentiation markers in time- and
concentration-dependent manners, and keratin 10 and lor-
icrin were particularly strongly induced. We also evaluated
the effect of another Syk inhibitor, Bay 61-3606, on kerati-
nocyte differentiation. Similar to R406, Bay 61-3606 induced
the expression of keratinocyte differentiation markers, espe-
cially keratin 10 and loricrin (Figure 2d).
Syk expression regulates keratinocyte terminal
differentiation
Based on the prominent effects of Syk inhibitors, we evalu-
ated the role of Syk expression in keratinocyte differentiation.
Syk expression in NHEKs was knocked down by small
interfering RNA (siRNA), and NHEKs were cultured until
cells reached confluence. This confluence-induced differen-
tiation model mimics the natural course of keratinocytedifferentiation and exhibits various differentiation markers
(Green, 1980). As shown in Figure 3aed, at the fourth day
after subculture when the cell density was increased, the
confluence-induced mRNA expression levels of involucrin,
TGase 1, keratin 10, and loricrin were more increased in Syk
knockdown NHEKs than in the control siRNA group. At the
protein level the induction of differentiation markers was
higher in NHEKs with Syk knockdown than in the control
group at the fifth day after subculture (Figure 3e). We exam-
ined if Syk also regulates PMA- and calcium-induced kerati-
nocyte differentiation. As shown in Supplementary Figure S2
(online), 48 hours after knocking down Syk in NHEKs, we
treated NHEKs with PMA and calcium for 24 hours. The
protein expression levels of involucrin and TGase 1 induced
by PMA or calcium were relatively higher in NHEKs with Syk
knockdown than in controls (Supplementary Figure S2).
Role of Syk in epidermal keratinocyte growth
After establishing the role of Syk in keratinocyte differentia-
tion, we further evaluated its potential regulatory role in
NHEK proliferation. As shown in Figure 4a, the number of
NHEKs as indexed by a crystal violet assay decreased by
around 20% after treatment with the Syk inhibitors R406 and
Bay 61-3606 for 3 days. Similarly, the relative cell number
showed a slight (around 10%) inhibition in NHEKs after Syk
knockdown (Figure 4b). A cell cycle analysis demonstrated
that the S-phase of NHEKs treated with R406 was mildly but
significantly reduced (Figure 4c). Based on BrdU uptake,
R406 significantly reduced the proliferative effect of
epidermal keratinocytes by 10% to 30% depending on the
cell culture medium containing growth factor or not
(Figure 4d). These results suggest that Syk may also play a role
in keratinocyte growth.
Cross-regulation between the activation of Syk and EGFR in
epidermal keratinocytes
EGFR signaling can affect keratinocyte differentiation and
growth; accordingly, the possible roles of Syk in EGFR-
activated signaling were explored. First, we assessed the
role of EGFR in keratinocyte differentiation. As shown in
Figure 5a, EGFR expression and EGFR phosphorylation
decreased along with cell differentiation caused by conflu-
ence. EGFR knockdown by siRNA especially increased the
expression of the differentiation markers keratin 10 and lor-
icrin at cell confluence (Figure 5b). Notably, EGF prominently
induced Syk phosphorylation, which persisted for more than 3
hours (Figure 5c and d). The phosphorylation of Syk induced
by EGF was almost abolished by EGFR knockdown or gefiti-
nib treatment (Figure 5c and d), confirming that Syk is a
downstream signaling molecule of EGFR. Src has crucial roles
in EGFR-activated signaling (Egloff and Grandis, 2008; Xi
et al., 2003) and Src family kinases are upstream signals for
Syk activation in multiple ITAM-containing immunoreceptors
(Mocsai et al., 2010); these observations were verified using
the Src-family kinase inhibitor PP2. We found that EGF-
induced Syk phosphorylation was partially suppressed by
PP2, implying that Src mediates EGF-induced Syk activation
(Figure 5d). Since Syk inhibition strongly promoted the
expression of keratin 10 and loricrin, similar to the effect of
EGFR knockdown, we further investigated the roles of Syk in
EGFR activation. As shown in Figure 5e, R406 obviouslywww.jidonline.org 193
Figure 1. Syk phosphorylation and expression are suppressed during keratinocyte differentiation. (aej) Immunohistochemical staining with phosphorylated
Syk and Syk was performed. Two specimens from normal skin (aed, i, j) and psoriatic skin (eeh) were analyzed. Phosphorylated Syk (a, c, e, g), Syk (b, d, f, h),
anti-rabbit IgG (i), or anti-mouse IgG (j) were demonstrated. Black bar ¼ 200 mm; white bar ¼ 100 mm. (k) One or 4 days after subculture, NHEKs were collected
for analysis of mRNA and protein expression by quantitative real-time PCR and Western blot, respectively. (l) NHEKs were treated with PMA and then Syk
expression was analyzed as in (k). Quantification data of Syk protein expression are shown in the lower panels. The individual control was set as 1.0. Data were
means from three independent experiments. *P < 0.05 (mean  s.e.m. n ¼ 3).
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Figure 2. Syk inhibitors promote the
expression of keratinocyte
differentiation markers. (a) NHEKs
were treated with Syk inhibitor, R406,
for 12 and 24 hours. Then, the mRNA
expression of differentiation markers
were analyzed by quantitative real-
time PCR. *P < 0.05 compared with
DMSO-treated control group (mean 
s.e.m. n ¼ 3) (b) NHEKs were treated
with R406 of different concentrations
for 30 hours. Then, protein expression
of differentiation markers were
determined by Western blot. (c)
NHEKs were treated with R406 (1 mM)
for 1, 3, and 5 days. Then cells were
collected for the protein analysis by
Western blot. (d) Similar to (c), NHEKs
were treated with another Syk
inhibitor, Bay 61-3606 (10 mM).
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down of Syk showed a similar but relatively mild effect.
Interactions between Syk and EGFR in epidermal
keratinocytes
We next investigated the subcellular localization of Syk and
EGFR to examine their interactions. As shown in Figure 6a,
before stimulation with EGF, EGFR was primarily detected on
the plasma membrane, whereas Syk was detected in the
plasma membrane, nuclei, and cytoplasm. The distribution of
Src expression was quite similar to that of EGFR. Mild co-
expression of EGFR and Syk was detected in the plasma
membrane. After stimulation with EGF, the co-localization of
EGFR and Syk was increased and moved from plasma
membrane to perinuclei between 30 minutes and 1 hour and
then returned back to the plasma membrane at 3 hours. These
findings reveal subcellular interactions between Syk and
EGFR in epidermal keratinocytes. To verify the molecularinteraction between EGFR and Syk in NHEKs, we used
immunoprecipitation to demonstrate that in addition to the
interaction between EGFR and Src, both Syk and Src inter-
acted with EGFR, and such interactions were particularly
enhanced after EGF stimulation (Figure 6b). We also inves-
tigated the interaction between Syk and EGFR in differenti-
ated keratinocytes. Confocal microscopy showed very subtle
change in the subcellular localization of Syk or co-
localization of EGFR and Syk after induction of differentia-
tion (see Supplementary Figure S3, online). Based on
immunoprecipitation in cells under PMA or calcium treat-
ment or at confluence, we found that Syk and Src association
with EGFR was weaker (Figure 6c).
DISCUSSION
Because of the embryonic or perinatal lethality of Syk-deficient
mice (Cheng et al., 1995; Turner et al., 1995), it is difficult to
observe the skin phenotype of adult Syk-deficient mice. Thewww.jidonline.org 195
Figure 3. Knockdown of Syk
promotes the expression of
keratinocyte differentiation markers
induced by cell confluence. (aed)
One and 4 days after knocking down
Syk in NHEKs, cells were collected for
the analysis of mRNA expression of
differentiation markers including
involucrin, TGase 1, keratin 10, and
loricrin by quantitative real-time PCR.
*P < 0.05 compared with siControl
group (mean  s.e.m. n ¼ 3). (e)
Similarly, 1, 3, and 5 days after
knocking down Syk, protein
expression of differentiation markers
in groups of control siRNA (siCtrl) or
Syk siRNA (siSyk) were determined by
Western blotting.
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196development of mice after epidermis-specific Syk knockout
may reveal the in vivo roles of Syk in skin keratinocytes. Syk
functions in the skin have rarely been studied. One previous
study indicated that Syk regulates UV-induced metal-
loproteinase expression in skin dermal fibroblasts (Papazoglou
et al., 2011). However, many potential biologic roles of Syk in
epidermal keratinocytes remain unknown. In our study we
used pharmacologic inhibitors of Syk and Syk knockdown to
examine the roles of Syk in epidermal keratinocytes.
The regulatory roles of Syk in immune systems have been
widely explored (Mocsai et al., 2010). Sykmayact as a positiveJournal of Investigative Dermatology (2016), Volume 136or negative regulator in the signaling pathways of innate and
adaptive immunoreceptors. It is not surprising that Syk is
abundantly expressed in epidermal keratinocytes because
keratinocytes express multiple innate immunoreceptors and
play critical roles in innate immunity to maintain skin ho-
meostasis (Kobayashi et al., 2009; McInturff et al., 2005). Skin
keratinocytes undergo the well-coordinated process of termi-
nal differentiation to form the skin barrier. In fact, in addition to
being a unique model of cell death, keratinocyte terminal
differentiation is defensive in nature, and various components
involved in innate immunity are upregulated during this
Figure 4. Inhibition of Syk mildly
reduces keratinocyte proliferation. (a)
NHEKs were treated with Syk
inhibitors, R406 and Bay 61-3606
(Bay), for 3 days, and then the relative
cell number was determined by the
crystal violet assay. (b) Ninety-six
hours after knocking down Syk in
NHEKs, relative cell numbers were
measured by crystal violet assay. Syk
expression was also shown. (c) NHEKs
were treated with the Syk inhibitor,
R406 (1 mM), for 3 days, and then cell
cycle was analyzed by flow cytometry.
(d) After starvation for 24 hours,
NHEKs were treated with R406 (1 mM)
or DMSO for 2 days and then cell
proliferation was analyzed by BrdU
incorporation assay. The group of
NHEKs treated with DMSO cultured
in media containing growth factors
was represented as the control. *P <
0.05 compared with DMSO group
(mean  s.e.m. n ¼ 3).
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demonstrated that Syk, an immunoregulator, is involved in
keratinocyte differentiation. More interestingly, Syk activation
and expression were gradually downregulated along with
keratinocyte differentiation, as evidenced by immunohisto-
chemical staining and cell studies (Figure 1). We also showed
that Syk inhibitors or Syk knockdown increase the expression
of keratinocyte differentiation markers, suggesting a negative
regulatory role of Syk in keratinocyte differentiation.
Most previous studies of Syk functions in nonskin epithelial
cells have focused on carcinogenesis. Syk expression is low or
undetectable in invasive breast carcinomas, and the reintro-
duction of Syk into cancer cell lines inhibits tumor growth and
metastasis in animal models (Coopman et al., 2000). These
findings suggest that Syk modulates epithelial cell growth and
acts as a tumor suppressor in breast carcinomas. Syk is down-
regulated in oral squamous cell carcinoma specimens and is
regarded as a candidate tumor suppressor gene (Ogane et al.,
2009). In squamous cell carcinoma of the head and neck, high
Syk expression in tumor specimens is associated with reduced
patient survival (Luangdilok et al., 2007). In addition to epithe-
lial tumors, Sykactsasa tumor suppressor to induce senescence-
like growth arrest in melanomas (Bailet et al., 2009).
As a critical regulator in immunoreceptor-mediated
signaling, Syk phosphorylation is triggered by the activation
of B-cell receptors, T-cell receptors, and Fc receptors and by
several pattern recognition receptors (Mocsai et al., 2010).
We demonstrated that EGFR activation strongly increases Syk
phosphorylation, and this effect lasted for more than 3 hours.
Induced and even basal phosphorylation of Syk were almost
completely abolished by the EGFR inhibitor gefitinib and
EGFR knockdown. This finding indicates that Syk is animportant signaling molecule downstream of the EGFR
pathway, in addition to its well-known roles in downstream
immunoreceptor signaling. Additionally, we showed that Src
kinase inhibitor, PP2, partially suppresses EGFR activation-
induced Syk phosphorylation. These findings reveal that Syk
is critically involved in the EGFR-mediated signaling pathway.
The EGFR/ligand system plays key roles in essential cellular
functions. Skin keratinocytes are a rich source of several
EGFR ligands (Pastore et al., 2008) and autocrine action of
EGFR ligands is involved in epidermal homeostasis, hair
follicle development, and keratinocyte stem cell behavior
(Nanba et al., 2013). EGFR signaling in the skin is
involved in epidermal keratinocyte growth regulation,
re-epithelialization of epidermal wound healing, inflamma-
tory responses, differentiation, and proliferation of keratino-
cyte stem cells (Gazel and Blumenberg, 2013; Jensen et al.,
2009; Pastore et al., 2008). Recently, we identified a role of
EGFR in psoriasis via upregulation of decoy receptor 3, an
immune modulator and proinflammatory mediator, in human
keratinocytes (Wu et al., 2013). To date, studies suggesting a
functional link between Syk and EGFR are limited. Our data
revealed the importance of Syk in EGFR-mediated signaling,
and these results may promote further studies of the role of
Syk in regulating EGFR-mediated inflammatory diseases.
Previous studies have shown that Syk is associated with
EGFR in some cell types (Luangdilok et al., 2007; Ruschel and
Ullrich, 2004). High Syk expression is correlated with reduced
survival in squamous cell carcinomas of the head and neck,
and Syk inhibition reduces cell migration and invasion
(Luangdilok et al., 2007). However, downregulation of
endogenous Syk expression in breast epithelial cells increases
the ligand-induced activity of EGFR (Ruschel and Ullrich,www.jidonline.org 197
Figure 5. Syk is involved in EGFR-mediated signaling in keratinocytes. (a) Expression of EGFR and phosphorylated EGFR in NHEKs 1, 3, and 5 days after
subculture was determined by Western blot. Lower panels were quantification data. The individual control was set as 1.0. Data were means from three
independent experiments. *P < 0.05 (mean  s.e.m. n ¼ 3). (b) Keratinocyte differentiation markers were evaluated 1, 3, and 5 days after knocking down EGFR.
(c) Twenty-four hours after knocking down EGFR, NHEKs were treated with EGF (50 ng/ml) after starvation for another 48 hours. (d) After pretreatment of
gefitinib (10 mM) or PP2 (10 mM), Syk phosphorylation was determined. (e) After pretreatment of R406 (1 mM), EGFR phosphorylation was evaluated after EGF
(50 ng/ml) treatment. Twenty-four hours after knocking down Syk, NHEKs were starved for another 48 hours and then treated similarly.
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Figure 6. Interaction between Syk
and EGFR in response to EGF
stimulation. (a) NHEKs were stained
with anti-EGFR (red, R), anti-Syk
(green, G), and anti-Src (white, W)
antibodies and with DAPI (blue) for
nuclei. Individual and overlaid
fluorescent images were shown after
EGF stimulation. White bar ¼ 20 mm.
Arrowheads indicate the co-
localization of Syk and EGFR. Data
were representative of three
independent experiments. Images
were acquired using a Zeiss LSM780
confocal microscope. (b) After EGF
(50 ng/ml) treatment,
immunoprecipitation with EGFR
antibody was performed to detect the
interaction with Syk. (c) NHEKs
treated with CaCl2 or PMA for
24 hours or without treatments (C)
confluent NHEKs (Conf.) were
subjected for immunoprecipitation
with EGFR antibody to detect the
interaction with Syk.
N-L Wu et al.
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ated its signaling; it also negatively regulated keratinocyte
differentiation. Furthermore, the expression of phosphorylated
Syk was obviously located in the cell membrane of epidermalkeratinocytes, especially in psoriasis specimens. This staining
pattern is similar to that observed in our confocal imaging
study, which reveals relatively strong co-localization of Syk
and EGFR in the cell membrane at basal status.www.jidonline.org 199
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200Based on the important roles of Syk in immunologic
functions, Syk inhibition is a promising treatment for immu-
nologic or inflammatory diseases (Kaur et al., 2013). In
addition to the accumulating experimental studies of the
therapeutic potential of Syk inhibitors, the use of fostamatinib
(R788), a Syk inhibitor, to treat rheumatoid arthritis has been
examined in a phase III clinical trial (Scott and Scott, 2014).
Nevertheless, because of the ubiquitous expression of Syk in
various tissues and cells, it is interesting to investigate the
effects of Syk inhibitors on other organs, including the skin.
Based on our results, the Syk inhibitor R406, which is an
active metabolite of fostamatinib, prominently induced the
expression of differentiation markers, suggesting potential
effects of Syk inhibitors on skin keratinocytes. In addition,
our immunohistochemical study shows high expression of
phosphorylated Syk in psoriatic epidermis samples. Our
recent study also reveals that Syk mediates IL-17Aeinduced
signaling to regulate chemokine C-C motif ligand 20
expression in epidermal keratinocytes (Wu et al., 2015),
implying potential roles of Syk inhibitors in the treatment of
psoriasis. Additional studies are needed to determine the
effects of diverse Syk inhibitors on the skin. Although no
topical Syk inhibitor is used in clinical applications, their
potential effects on the skin are of interest. Based on our
results, animal models should be used to evaluate the effects
of topical Syk inhibitors on the recovery of skin barrier
function or skin diseases characterized by aberrant kerati-
nocyte differentiation and inflammation, such as psoriasis.
In conclusion, we revealed the crucial role of Syk in skin
biology. Syk acts as a negative regulator in epidermal kera-
tinocyte differentiation, and is also involved in EGFR
signaling, which may contribute, at least in part, to its regu-
latory role in keratinocyte terminal differentiation. These
findings not only extend the current understanding of Syk but
also pave the way to develop pharmacologic agents to treat
skin disorders via Syk targeting.
METHODS
Immunohistochemical staining
Paraffin-embedded skin specimens were prepared retrospectively for
immunohistochemical studies. The experiments were conducted
according to the Declaration of Helsinki principles and approved by
the Ethics Committee of Mackay Memorial Hospital. Briefly,
formalin-fixed and paraffin-embedded tissue sections were pro-
cessed and subjected to staining with Dako Autostainer Link48
(Dako, Glostrup, Denmark) and the primary antibodies against
phosphorylated Syk (Abgent, San Diego, CA) or Syk (Santa Cruz
Biotechnology, Santa Cruz, CA).
Cell culture
NHEKs were obtained from normal adult human foreskin and iso-
lated as described previously (Wu et al., 2011). The experiments
were conducted according to the Declaration of Helsinki principles
and approved by the Ethics Committee of Mackay Memorial Hos-
pital (Institutional Review Board codes 10MMHIS179 and
15MMHIS019e). Written, informed consent was obtained from each
donor before experiments were performed.
Reagents
Antibodies against TGase 1, involucrin, and Syk and horseradish
peroxidase-coupled secondary antibodies were purchased fromJournal of Investigative Dermatology (2016), Volume 136Santa Cruz Biotechnology. Antibodies for human keratin 10 and
loricrin were purchased from Covance (Emeryville, CA). Anti-
bodies for EGFR, Src, phosphorylated EGFR, and phosphorylated
Syk were purchased from Cell Signaling Technology (Beverly,
MA). The antibody against b-actin was obtained from Upstate
Biotechnology (Charlottesville, VA). The enhanced chem-
iluminescence reagent was obtained from Perkin Elmer (Wellesley,
MA). Soluble recombinant human EGF was purchased from
PeproTech (Rocky Hill, NJ). Gefitinib was purchased from Cayman
Chemical Company (Ann Arbor, MI). PP2 was purchased from
Calbiochem (San Diego, CA). R406 was purchased from Selleck
Chemicals LLC (Houston, TX).
Immunoblotting
Protein expression was determined in cell lysates by electrophoresis
and immunoblotting as previously described (Wu et al., 2013).
Immunoprecipitation
NHEKs with the indicated treatments were harvested. Immunopre-
cipitation experiments were performed with specific antibodies, and
then an immunoblotting analysis was performed as described pre-
viously (Lin et al., 2013).
Real-time PCR
The primer sequence pairs used for quantitative real-time PCR were
involucrin (NM_005547): 50-TCAATACCCATCAGGAGCAAATG-30
and 50-GAGCTCGACA GGCACCTTCT-30; TGase 1 (NM_000359):
50-TCTTCAAGAACCCCCTTCCC-30 and 50-TCTGTAACCCAGAG
CCTTCG A-30; keratin 10 (NM_000421.3): 50-ATAAT GCCAAC
ATCCTGCTTCA-30 and 50-AGGCCGTTGATGTCAGCCT-30; loricrin
(NM_000427.2): 50-TCATGATGCTACCCGAGGTT TG-30 and 50-
CAGAA CTAGATGCAGCCGGAGA-30; and the housekeeping gene
cyclophilin A (NM_21130): 50-CCCACCGTGTTCTTCGACAT-30 and
50-CCAGTGCTCAGAGCACGAAA-30. The experiment and data
analysis were conducted as previously described (Wu et al., 2011).
Small interfering RNA
siRNA targeting mRNA degradation of human Syk and EGFR and
scramble nonspecific siRNA were purchased from Dharmacon
Research Inc. (Lafayette, CO). The procedure was performed as
described previously (Wu et al., 2011).
Crystal violet assay
To evaluate the relative cell numbers, NHEKs with the indicated
treatments were cultured in media for days. After cells were rinsed
with phosphate-buffered saline, they were fixed with methanol for
10 minutes at room temperature and stained with 0.1% crystal vi-
olet. The relative cell number was determined by measuring the
absorbance of the dissolved dye at 540 nm after elution with 33%
acetic acid.
BrdU cell proliferation assay
Briefly, NHEKs were starved for 48 hours and then treated with
indicated drugs and cultured in media with or without growth factors
for an additional 24 hours. Cells were treated with BrdU, and the
cell proliferation rate was determined by colorimetric BrdU cell
proliferation ELISA according to the manufacturer’s instructions
(Roche, Mannheim, Germany).
Cell cycle analysis by flow cytometry
NHEKs with the indicated treatments were harvested and subjected
to a cell cycle analysis by flow cytometry (BD Biosciences, Franklin
Lakes, NJ) as described previously (Su et al., 2007).
N-L Wu et al.
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NHEKs were fixed with 4% paraformaldehyde at 37 C for 20 mi-
nutes and then permeabilized with 0.2% Triton X-100 for 15 mi-
nutes. After blocking with 5% BSA with normal IgG (1:300) for 1
hour, immunostaining was performed with primary antibodies
against Syk (Santa Cruz Biotechnology), EGFR (Santa Cruz Biotech-
nology), and hSrc-647nm (Abcam, Cambridge, UK) in 1% BSA
overnight at 4 C. After washing with phosphate-buffered saline, cells
were incubated with secondary antibodies in 1% BSA in phosphate-
buffered saline solution for 1 hour at room temperature and then
mounted with DAPI Fluoromount-G (SouthernBiotech, Birmingham,
AL). Images were acquired using a confocal microscope (model
LSM780; Carl Zeiss MicroImaging GmbH, Jena, Germany).
Statistical analysis
Data were expressed as means  s.e.m. Student’s t-tests were used to
assess the statistical significance of differences. P < 0.05 was
considered to be statistically significant.
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